Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Research Report 2012-2023

1 Market Overview

1.1 Objectives of Research

1.1.1 Definition

1.1.2 Specifications

1.2 Market Segment

1.2.1 by Type

1.2.1.1 Existing Drugs

1.2.1.2 Akynzeo (Netupitant-Palonosetron FDC)

1.2.1.3 Aloxi (Palonosetron)

1.2.1.4 Emend (Aprepitant)

1.2.1.5 Kytril Generic (Granisetron)

1.2.1.6 Zofran Generic (Ondansetron)

1.2.1.7 Pipeline Drugs

1.2.1.8 SUSTOL (Granisetron Injection extended release)

1.2.1.9 Rolapitant

1.2.2 by Application

1.2.2.1 Serotonin Receptor Antagonists

1.2.2.2 NK1 Receptor Antagonists

1.2.3 by Regions

2 Industry Chain

2.1 Industry Chain Structure

2.2 Upstream

2.3 Market

2.3.1 SWOT

2.3.2 Dynamics

3 Environmental Analysis

3.1 Policy

3.2 Economic

3.3 Technology

3.4 Market Entry

4 Market Segmentation by Type

4.1 Market Size

4.1.1 Existing Drugs Market, 2012-2017

4.1.2 Akynzeo (Netupitant-Palonosetron FDC) Market, 2012-2017

4.1.3 Aloxi (Palonosetron) Market, 2012-2017

4.1.4 Emend (Aprepitant) Market, 2012-2017

4.1.5 Kytril Generic (Granisetron) Market, 2012-2017

4.1.6 Zofran Generic (Ondansetron) Market, 2012-2017

4.1.7 Pipeline Drugs Market, 2012-2017

4.1.8 SUSTOL (Granisetron Injection extended release) Market, 2012-2017

4.1.9 Rolapitant Market, 2012-2017

4.2 Market Forecast

4.2.1 Existing Drugs Market Forecast, 2018-2023

4.2.2 Akynzeo (Netupitant-Palonosetron FDC) Market Forecast, 2018-2023

4.2.3 Aloxi (Palonosetron) Market Forecast, 2018-2023

4.2.4 Emend (Aprepitant) Market Forecast, 2018-2023

4.2.5 Kytril Generic (Granisetron) Market Forecast, 2018-2023

4.2.6 Zofran Generic (Ondansetron) Market Forecast, 2018-2023

4.2.7 Pipeline Drugs Market Forecast, 2018-2023

4.2.8 SUSTOL (Granisetron Injection extended release) Market Forecast, 2018-2023

4.2.9 Rolapitant Market Forecast, 2018-2023

5 Market Segmentation by Application

5.1 Market Size

5.1.1 Serotonin Receptor Antagonists Market, 2012-2017

5.1.2 NK1 Receptor Antagonists Market, 2012-2017

5.2 Market Forecast

5.2.1 Serotonin Receptor Antagonists Market Forecast, 2018-2023

5.2.2 NK1 Receptor Antagonists Market Forecast, 2018-2023

6 Market Segmentation by Region

6.1 Market Size

6.1.1 Asia-Pacific

6.1.1.1 Asia-Pacific Market, 2012-2017

6.1.1.2 Asia-Pacific Market by Type

6.1.1.3 Asia-Pacific Market by Application

6.1.2 North America

6.1.2.1 North America Market, 2012-2017

6.1.2.2 North America Market by Type

6.1.2.3 North America Market by Application

6.1.3 Europe

6.1.3.1 Europe Market, 2012-2017

6.1.3.2 Europe Market by Type

6.1.3.3 Europe Market by Application

6.1.4 South America

6.1.4.1 South America Market, 2012-2017

6.1.4.2 South America Market by Type

6.1.4.3 South America Market by Application

6.1.5 Middle East & Africa

6.1.5.1 Middle East & Africa Market, 2012-2017

6.1.5.2 Middle East & Africa Market by Type

6.1.5.3 Middle East & Africa Market by Application

6.2 Market Forecast

6.2.1 Asia-Pacific Market Forecast, 2018-2023

6.2.2 North America Market Forecast, 2018-2023

6.2.3 Europe Market Forecast, 2018-2023

6.2.4 South America Market Forecast, 2018-2023

6.2.5 Middle East & Africa Market Forecast, 2018-2023

7 Market Competitive

7.1 Global Market by Vendors

7.2 Market Concentration

7.3 Price & Factors

7.4 Marketing Channel

8 Major Vendors

8.1 Merck & Co., Inc.

8.1.2 Profile

8.1.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.2 GlaxoSmithKline plc

8.2.1 Profile

8.2.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.3 Tesaro, Inc.

8.3.1 Profile

8.3.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.4 Helsinn Group

8.4.1 Profile

8.4.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.5 F. Hoffmann-La Roche Ltd.

8.5.1 Profile

8.5.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.6 Heron Therapeutics, Inc.

8.6.1 Profile

8.6.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.7 Dr. Reddy's Laboratories Ltd.

8.7.1 Profile

8.7.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.8 Acacia Pharma

8.8.1 Profile

8.8.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.9 Sun Pharmaceutical Industry Ltd.

8.9.1 Profile

8.9.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.10 Otsuka Holdings Co., Ltd.

8.10.1 Profile

8.10.2 Business Performance (Sales Revenue, Cost, Gross Margin)

9 Conclusion

Table Products Segment of Chemotherapy-Induced Nausea and Vomiting Drugs

Table Existing Drugs Overview

Table Akynzeo (Netupitant-Palonosetron FDC) Overview

Table Aloxi (Palonosetron) Overview

Table Emend (Aprepitant) Overview

Table Kytril Generic (Granisetron) Overview

Table Zofran Generic (Ondansetron) Overview

Table Pipeline Drugs Overview

Table SUSTOL (Granisetron Injection extended release) Overview

Table Rolapitant Overview

Table Global Chemotherapy-Induced Nausea and Vomiting Drugs Market by Type, 2011-2022 (USD Million)

Table Application Segment of Chemotherapy-Induced Nausea and Vomiting Drugs

Table Serotonin Receptor Antagonists Overview

Table NK1 Receptor Antagonists Overview

Table Global Chemotherapy-Induced Nausea and Vomiting Drugs Market by Application, 2011-2022 (USD Million)

Table Global Chemotherapy-Induced Nausea and Vomiting Drugs Market by Region, 2011-2022 (USD Million)

Table Cost of Chemotherapy-Induced Nausea and Vomiting Drugs

Table Market Dynamics

Table Policy of Chemotherapy-Induced Nausea and Vomiting Drugs

Table GDP of Major Countries

Table Existing Drugs CAGR by Revenue and Volume, 2012-2017

Table Akynzeo (Netupitant-Palonosetron FDC) CAGR by Revenue and Volume, 2012-2017

Table Aloxi (Palonosetron) CAGR by Revenue and Volume, 2012-2017

Table Emend (Aprepitant) CAGR by Revenue and Volume, 2012-2017

Table Kytril Generic (Granisetron) CAGR by Revenue and Volume, 2012-2017

Table Zofran Generic (Ondansetron) CAGR by Revenue and Volume, 2012-2017

Table Pipeline Drugs CAGR by Revenue and Volume, 2012-2017

Table SUSTOL (Granisetron Injection extended release) CAGR by Revenue and Volume, 2012-2017

Table Rolapitant CAGR by Revenue and Volume, 2012-2017

Table Existing Drugs CAGR by Revenue and Volume, 2012-2022

Table Akynzeo (Netupitant-Palonosetron FDC) CAGR by Revenue and Volume, 2012-2022

Table Aloxi (Palonosetron) CAGR by Revenue and Volume, 2012-2022

Table Emend (Aprepitant) CAGR by Revenue and Volume, 2012-2022

Table Kytril Generic (Granisetron) CAGR by Revenue and Volume, 2012-2022

Table Zofran Generic (Ondansetron) CAGR by Revenue and Volume, 2012-2022

Table Pipeline Drugs CAGR by Revenue and Volume, 2012-2022

Table SUSTOL (Granisetron Injection extended release) CAGR by Revenue and Volume, 2012-2022

Table Rolapitant CAGR by Revenue and Volume, 2012-2022

Table Serotonin Receptor Antagonists CAGR by Revenue and Volume, 2012-2017

Table NK1 Receptor Antagonists CAGR by Revenue and Volume, 2012-2017